MarketLine Company Profile: ArQule, Inc.

ARQULE Inc.; BIOTECHNOLOGY industries

ArQule is a biotechnology company engaged in the research and development of small-molecule cancer therapeutics. The company’s lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (c-MET or MET) and its biological pathway. C-MET is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The company primarily operates in the US, where it is headquartered in Woburn, Massachusetts, and employs around 68 people. The company recorded revenues of $15.9 million in the fiscal year ended December 2013, a decrease of 56.3% compared to 2012. The company's operating loss was $25.1 million in fiscal 2013, as compared to an operating loss of $11.4 million in 2012. Its net loss was $24.6 million in fiscal 2013, as compared to the net loss of $10.9 million in 2012. [ABSTRACT FROM AUTHOR]

Copyright of ArQule, Inc. MarketLine Company Profile is the property of MarketLine, a Progressive Digital Media business and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)